Omacetaxine mepesuccinate in chronic myeloid leukemia

Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors

(2013) J. Cortes et al.   AMERICAN JOURNAL OF HEMATOLOGY

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

(2013)   BLOOD

Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib

(2013) Jorge E. Cortes et al.   Clinical Lymphoma Myeloma & Leukemia

Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations

(2013) Ibrahim C Haznedaroglu   EXPERT OPINION ON PHARMACOTHERAPY

U.S. Food and Drug Administration Approval Summary: Omacetaxine Mepesuccinate as Treatment for Chronic Myeloid Leukemia

(2013) F. Alvandi et al.   ONCOLOGIST

Abl kinases are required for vascular function, Tie2 expression, and angiopoietin-1-mediated survival

(2013) E. M. Chislock et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation

(2012) J. Cortes et al.   BLOOD

Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors

(2012) John Nemunaitis et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia

(2012) Elias Jabbour et al.   Clinical Lymphoma Myeloma & Leukemia

Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common β-subunit c of cytokine receptors

(2012) T Klag et al.   LEUKEMIA

Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase

(2011) Q. Jiang et al.   BLOOD

Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis

(2011) H J Khoury et al.   BONE MARROW TRANSPLANTATION

Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells

(2011) E K Allan et al.   LEUKEMIA

Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis

(2011) Franck E. Nicolini et al.   LEUKEMIA & LYMPHOMA

Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with imatinib

(2010) Baijun Fang et al.   ANNALS OF HEMATOLOGY

Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia

(2010) R. Chen et al.   BLOOD

The Durable Clearance of the T315I BCR-ABL Mutated Clone in Chronic Phase Chronic Myelogenous Leukemia Patients on Omacetaxine Allows Tyrosine Kinase Inhibitor Rechallenge

(2010) Franck E. Nicolini et al.   Clinical Lymphoma Myeloma & Leukemia

The effect of homoharringtonine in patients with chronic myeloid leukemia who have failed or responded suboptimally to imatinib therapy

(2010) Yu-Feng Li et al.   LEUKEMIA & LYMPHOMA

The Antitumor Activity of Homoharringtonine against Human Mast Cells Harboring the KIT D816V Mutation

(2010) Y. Jin et al.   MOLECULAR CANCER THERAPEUTICS

Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation

(2009) F. E. Nicolini et al.   BLOOD

The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up

(2009) F. Palandri et al.   HAEMATOLOGICA

Impact of BaselineBCR-ABLMutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

(2009) Timothy Hughes et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice

(2009) Y Chen et al.   LEUKEMIA

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

(2009) A Hochhaus et al.   LEUKEMIA

A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804

(2008) Richard M. Stone et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY